Agreement covers two sanctioned formulations and a third that will be submitted for approval in the third quarter.
Debiopharm says that Mepha Pharma will distribute three formulations of Pamorelin LA in Switzerland, which are developed for the treatment of prostate cancer, endometriosis, and female infertility.
The agreement includes one-, three-, and six-month formulations of the drug containing triptorelin pamoate, a luteinizing hormone-releasing hormone agonist. The one- and three-month sustained-release formulations are marketed in the U.S. under the name Trelstar and as Decapeptyl and Pamorelin in Europe.
The six-month formulation is expected to be submitted to Swiss regulatory officials in the third quarter, according to Debiopharm. The firm has already applied for U.S. and European approval of this formulation.
Sales for the compound in China, Germany, the U.K., and other markets by Ipsen were €61.4 million in the first quarter, up 0.9% from 2008.
Past News from Debiopharm
Aurigene to Assist with Advancement of Debiopharm’s Oncology Compound (Nov. 20, 2008)
Pharmaleads to Assist with Development of Debiopharm’s Chronic Pain Therapeutic (Nov. 17, 2008)
Debiopharm and EPFL Collaborate to Research New Cancer Treatments (Sep. 2, 2008)
Debiopharm Receives cGMP Certification for QC of Drug Products (Sep. 11, 2007)
Debiopharm Signs Four International Marketing Agreements for EVB Drug (Oct. 23, 2006)